Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comprehensive Molecular and Genomic Analysis of NCI-MATCH Subprotocol Y: Capivasertib in Patients With an AKT1 E17K-Mutated Tumor.

JCO precision oncology - 1 Mar 2025

McCourt Carolyn K, Gross Jacob, Kalinsky Kevin, Guan Ping, McShane Lisa M, Wang Victoria, O'Dwyer Peter J, Lahey Matthew T, Maican Cayden, Bu Xiangning, Patton David, Harris Lyndsay N

Abstract excerpt

PURPOSE: NCI-MATCH (EAY131) is a precision medicine trial using genomic testing to allocate patients with advanced malignancies to targeted treatments. Arm Y evaluated capivasertib, a pan AKT inhibitor, in patients with an AKT1 E17K-mutated tumor. Here, we report on the translational objectives of the study, a molecular and genomic analysis of specimens to identify potential biomarkers of response or resistance...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to AKT1 gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genomics

Share to Mutation

Share to Neoplasms

Share to Proto-Oncogene Proteins c-akt

Share to Pyrimidines

Share to Pyrroles

Source

Open in PubMed Open full text

Identifiers

PMID: 40153687
DOI: 10.1200/PO-24-00614
PMCID: PMC12085156

Genes

AKT1
EGFR
TP53
CDIPT
POTEI
POTEJ
SUSD4
SYNJ1
TYRO3

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comprehensive Molecular and Genomic Analysis of NCI-MATCH Subprotocol Y: Capivasertib in Patients With an AKT1 E17K-Mutated Tumor.PMID 40153687Read ↗

Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K.Semantic proximity Read ↗

Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1 E17K-Mutant, ER-Positive Metastatic Breast Cancer.Semantic proximity Read ↗

Characteristics and Outcome of AKT1 E17K-Mutant Breast Cancer Defined through AACR Project GENIE, a Clinicogenomic Registry.Semantic proximity Read ↗

Integrative omics analyses broaden treatment targets in human cancer.Semantic proximity Read ↗

Integrative Molecular Analysis of Patients With Advanced and Metastatic CancerSemantic proximity Read ↗

AKT Inhibition in Solid Tumors With AKT1 Mutations.Semantic proximity Read ↗

The NCI-MATCH: A National, Collaborative Precision Oncology Trial for Diverse Tumor Histologies.Semantic proximity Read ↗

Pharmacovigilance Signal Detection and Mutually Exclusive Driver Mutations of the PI3K/AKT Pathway in Breast Cancer Treated With Capivasertib.Semantic proximity Read ↗

Clinicogenomic Landscape and Function of PIK3CA, AKT1, and PTEN Mutations in Breast Cancer.Semantic proximity Read ↗

AKT mutant allele-specific activation dictates pharmacologic sensitivities.Semantic proximity Read ↗

A comprehensive pan-cancer analysis identifies AP1S1 as a novel biomarker for predicting prognosis and immunotherapy responseSemantic proximity Read ↗

Exploratory analysis of biomarkers associated with clinical outcomes from the study of palbociclib plus endocrine therapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.